|
|
| Line 3: |
Line 3: |
| {{CMG}} | | {{CMG}} |
|
| |
|
| ==Description==
| | #redirect [[Sofosbuvir#Clinical Pharmacology]] |
| SOVALDI is the brand name for sofosbuvir, a nucleotide analog inhibitor of HCV NS5B polymerase.
| |
|
| |
|
| The IUPAC name for sofosbuvir is (S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)-(phenoxy)phosphorylamino)propanoate. It has a molecular formula of C22H29FN3O9P and a molecular weight of 529.45. It has the following structural formula:
| |
|
| |
| {|
| |
| |-
| |
| |[[File:Sofosbuvir 1.jpg|thumb|1600px|left]]
| |
| |-
| |
| |}
| |
| Sofosbuvir is a white to off-white crystalline solid with a solubility of ≥ 2 mg/mL across the pH range of 2–7.7 at 37 °C and is slightly soluble in water.
| |
|
| |
| SOVALDI tablets are for oral administration. Each tablet contains 400 mg of sofosbuvir. The tablets include the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, and microcrystalline cellulose. The tablets are film-coated with a coating material containing the following inactive ingredients: polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide, and yellow iron oxide.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = SOVALDI (SOFOSBUVIR) TABLET, FILM COATED [GILEAD SCIENCES, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=80beab2c-396e-4a37-a4dc-40fdb62859cf | publisher = | date = | accessdate = 7 January 2014 }}</ref>
| |
| ==References== | | ==References== |
| {{Reflist}} | | {{Reflist}} |
Revision as of 16:10, 1 August 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
- redirect Sofosbuvir#Clinical Pharmacology
References
Adapted from the FDA Package Insert.